Answers are grounded in this paper and cite their sources.
Early-onset hemophagocytic lymphohistiocytosis (HLH) can arise as a rare, but important, complication of hematopoietic cell transplantation (HCT) and is difficult to diagnose and treat. It can be considered to be a type of post-transplant cytokine storm syndrome, similar to pre-engraftment immune reaction, engraftment syndrome, other forms of early-onset HLH, and idiopathic pneumonia syndrome. HLH is assumed to be caused by overwhelming activation of monocytes/macrophages. Combined treatment with low-dose etoposide and dexamethasone palmitate has been reported to an effective treatment for early-onset HLH after HCT, as it suppresses abnormally activated monocytes/macrophages. The elucidation of the immunological profile of this condition and the establishment of methods for achieving optimal control of engraftment-related post-transplant cytokine storm syndrome are expected to be achieved in future.
No takes yet. Share an insight, caveat, or question.
Masami Inoue (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: